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ABSTRACT 
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease affecting 0.2% of 
the population. Several B cell aberrances have been linked to pSS, such as autoantibody 
production, hypergammaglobulinemia and B cell associated genetic polymorphisms. In 
addition, pSS patients display a 16 fold increased risk to develop B cell lymphomas. 
Autoantibodies to TRIM21/ Ro52 are detected in approximately 70% of patients with 
pSS. The cellular role of TRIM21 was largely unknown when this thesis was initiated. 
However, TRIM21 had been implicated to belong to the TRIpartite Motif (TRIM) 
family, of which many proteins are E3 ligases, mediating ubiqiutination. The aims of 
this thesis were to characterize the role of B cells in primary Sjögren’s syndrome 
pathogenesis and to elucidate the cellular role of the autoantigen TRIM21.  
 
By using vaccination as a tool to study immune responses pSS in vivo, we detected a 
vigorous B cell hyperreactivity, specifically in IgG producing cells. Further, in vitro 
induction of IgG class switch revealed an increased response to endosomal Toll-like 
receptor (TLR) stimulation in B cells from patients. This phenomenon may explain the 
hypergammaglobulinemia observed in pSS patients, and possibly also the high 
autoantibody titers.   
 
In both in vivo and in vitro ubiquitination assays, we could show that TRIM21 is an E3 
ligase. To better understand its role in immunity, a TRIM21-/- IRES-GFP mouse was 
generated. Studies revealed a hyperresponsive immune system. Mild immune activation 
induced Th17-dependent dermatitis and subsequently systemic autoimmunity with 
hypergammaglobulinemia, anti-nuclear antibodies and glomerulonephritis. We 
observed that TRIM21 regulates several interferon regulatory factors (IRFs), central 
transcription factors of pro-inflammatory responses, by ubiquitination. The loss of 
TRIM21 expression therefore resulted in loss of negative regulation of the transcription 
factors, and thereby accentuated immune responses. 
 
By using GFP as a reporter in the TRIM21-deficient-IRES-GFP mice, we observed that 
TRIM21 protein is almost exclusively expressed in hematopoietic cells. Further, 
overexpression of TRIM21 in a B cell lymphoma cell line resulted in markedly reduced 
proliferation and increased apoptosis. These findings prompted us to study the role of 
TRIM21 in lymphomagenesis. In three independent cohorts of diffuse large B cell 
lymphomas (DLBCL), a strong correlation between low TRIM21 expression and short 
overall and progression-free survival was demonstrated.  
 
In conclusion, these studies show that endosomal TLR hyperreactivity underlie 
hypergammaglobulinemia in primary Sjögren’s syndrome. Further, the major 
autoantigen TRIM21 is an E3 ligase, negatively regulating interferon and TLR 
responses. Loss of TRIM21 expression is associated both to aggravated immune 
responses and poor outcome in lymphoma development, implicating a central role for 
TRIM21 in the development of both systemic autoimmune diseases and lymphomas. 
 
